WaveBreak is taking a transformative approach to drug discovery, targeting the fleeting intermediates that are central to many disease pathways but have been beyond the reach of conventional drug discovery approaches.
Our first focus is on two of the most prominent unmet medical needs of our time: Neurodegeneration in Alzheimer’s disease and Parkinson’s disease.
Press Releases
March 4, 2022
* Renamed WaveBreak in 2023